Cellexus Limited Strengthens Board with Addition of Dr Sandy Primrose as a New Non-Executive Director
7/20/2009 12:29:50 PM
Cellexus Limited, ’The Cell Company’, is delighted to announce the appointment of Dr Sandy Primrose as a Non-Executive Director. His appointment further enhances the extensive commercial experience of the Board members and adds key expertise in the biopharmaceutical sector which will be of significant strategic importance in management of the Company's growth.
Cellexus Limited is a leading supplier of innovative single use, disposable bioreactors which are designed to improve cell culture processes and enable production of higher yields of soluble proteins. The CellMaker systems the Company supplies apply single-use, disposable cell culture bioreactor bags with highly efficient methods to mix and oxygenate. Whilst other systems require shakers, rockers, rollers or large environmental chambers, the CellMaker systems employ a novel airlift technology which is simple, scalable, inexpensive to use and proven to out-perform cell culture in flasks. The CellexusBags, which are the unique single-use, disposable cell culture bags in which cells are grown in the CellMaker Regular system, enable fast set-up times and eliminate cleaning requirements. The CellMaker Regular very efficiently aerates the CellexusBag with controlled air flow providing oxygen for cell growth and gentle and effective mixing to maintain cells in suspension. Pressure control enhances oxygen availability to cells as well as decreases foaming and temperature control enables production of high yields of soluble protein under optimal conditions.
Mr Bob Cumming, Cellexus Limited General Manager, stated “We are very pleased that Dr Primrose will be joining the Cellexus Board. His wealth of knowledge in the bioprocess market sector will be a valuable asset as we continue to grow. He is a highly experienced executive who has held senior management positions at Searle Research & Development as well as Amersham International. In the past he has also held Non-Executive positions at Codon Pharmaceuticals, Adaptive Biosystems, the Health Protection Agency and Vistatec York Ltd. He is currently a Non-Executive Director at Novolytics Ltd, Immune Targeting Systems and Lab901 Limited.”
Dr Primrose, added “I am very pleased to join the Cellexus team and look forward to working with the Board as we further progress Company strategy and drive growth. Cellexus is very well positioned to gain significant market share with the Company’s range of very innovative single-use, disposable bioreactor products which are highly important to customers in the bioprocess field. "
About Cellexus Limited
Cellexus Limited (Huntingdon, UK) provides a range of instruments and value added consumables to help researchers in the biopharmaceutical industry and academia develop new biopharmaceutical products from cell lines.
Biopharmaceuticals are a rapidly evolving range of therapeutics generated by culturing cells in bioreactors and include proteins, antibodies or vaccines, with the possible of future medical treatments offered by stem cell research also falling into this category. Sales of biopharmaceuticals reached US$60 billion in 2005 and are growing at 20% per year.
The Company’s core technology is at the centre of a range of different product configurations and formats the Company offers that can be used for production of biological cells and proteins in a single-use, disposable bag format. This same configuration can also be used in biopharmaceutical manufacture for mixing various materials under clean and sterile conditions. These product range offer significant technological improvements for cell culture and cell growth to the biopharmaceutical industry.
The single-use, disposable (consumable) elements of the CellMaker bioreactors that the Company markets are the CellexusBag™ and HybridBag. These single use, disposable self contained bags form a product range (there are currently six variants of the CellexusBag™ and two variants of the HybridBag) which are manufactured under clean room conditions and to the ISO standards required by the biopharmaceutical industry. The bioreactor products come with built-in chiller units and an oxygen generator, which removes the need for piped gas. The gentle flow of gas bubbles mixes the contents and the bag design reduces foaming. The CellMaker equipment used to manage the cell culture process is very simple, efficient and inexpensive to use. A patent protecting the Company’s Intellectual Property in this area was filed in December 2005 with a second patent application filed in June 2007.
comments powered by